SEC INSIDER TRANSACTIONS

THERMO FISHER SCIENTIFIC INC. (TMO) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

TMO · THERMO FISHER SCIENTIFIC INC.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 40 filings · fetched 2026-11-13T20:19:33Z

Recent reported activity

0purchase rows on this page

23sale rows on this page

165matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F11	S Sale (market/private)Common Stock · Non-derivative	37D	577.56	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F10	S Sale (market/private)Common Stock · Non-derivative	1,289D	576.83	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F9	S Sale (market/private)Common Stock · Non-derivative	1,464D	576.05	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F8	S Sale (market/private)Common Stock · Non-derivative	1,113D	574.98	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F7	S Sale (market/private)Common Stock · Non-derivative	590D	574.03	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F6	S Sale (market/private)Common Stock · Non-derivative	216D	573.08	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F5	S Sale (market/private)Common Stock · Non-derivative	68D	571.5	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F14	S Sale (market/private)Common Stock · Non-derivative	40D	569.69	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F13	S Sale (market/private)Common Stock · Non-derivative	38D	569.13	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	66D	567.94	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F12	S Sale (market/private)Common Stock · Non-derivative	79D	566.26	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F11	S Sale (market/private)Common Stock · Non-derivative	75D	577.56	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F10	S Sale (market/private)Common Stock · Non-derivative	2,575D	576.82	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F9	S Sale (market/private)Common Stock · Non-derivative	2,930D	576.05	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F8	S Sale (market/private)Common Stock · Non-derivative	2,223D	574.98	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F7	S Sale (market/private)Common Stock · Non-derivative	1,186D	574.03	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F6	S Sale (market/private)Common Stock · Non-derivative	431D	573.08	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F5	S Sale (market/private)Common Stock · Non-derivative	135D	571.49	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1	S Sale (market/private)Common Stock · Non-derivative	53D	569.76	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	105D	569.24	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	130D	567.92	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	157D	566.25	Direct	Form 4 ↗0001216055-26-000006
2026-08-05Filed 2026-08-07	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. One of two Form 4's filed on August 7, 2026 for the reporting of transactions occurring on August 5 and August 6, 2026. The first Form 4 includes transactions occurring on August 5, 2026, and the second Form 4 includes transactions occurring on August 6, 2026. In aggregate, all transactions could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4. References:	M Exercise / conversionCommon Stock · Non-derivative	10,000A	309.63	Direct	Form 4 ↗0001216055-26-000006
2026-07-27Filed 2026-07-28	Pettiti GianlucaOfficer · President & COO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025. References: F1	S Sale (market/private)Common Stock · Non-derivative	400D	565	Direct	Form 4 ↗0000097745-26-000140
2026-06-27Filed 2026-06-30	SPERLING SCOTT MDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Convertible into Common Stock on a 1-for-1 basis. F2 Represents stock units credited to the Reporting Person's account as of June?27, 2026, at a price of $513.03 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control. References: F1, F2	A Award / grantPhantom Stock Units · Derivative	82.84A	—	Direct	Form 4 ↗0000097745-26-000136

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.